Early Loading of a Percutaneous Bone-Anchored Hearing Implant System Following Single-Stage Surgery in Children: A Prospective 2-Year Study Authors: Ayla Tabaksert, Lisa Kennedy, Diana Lynch, Kia N. Iversen, Anirvan Banerjee Published: 2026 ABSTRACT Objective:To assess implant stability, safety, and functional outcomes of early sound processor activation following single-stage bone-anchored hearing implant (BAHI) surgery with a percutaneous implant system in a pediatric population.Study design:Prospective single-center, single-armed, observational study with 24-month follow-up.Setting:University hospital clinic.Patients:Fifteen pediatric patients (aged 7 to 14 y), who had used a sound processor on a softband for at least 2 weeks before surgery, including one bilaterally implanted patient, leading to a total number of 16 implants.Intervention:Early sound processor loading following single-stage BAHI surgery.Main outcome measures:Implant stability, assessed by the implant stability quotient (ISQ). Secondary outcomes included implant survival, audiological performance, soft tissue tolerance (Holgers score), and patient-reported outcomes.Results:ISQ showed a high degree of implant stability already at surgery, and numerical increases over time in combination with a 100% implant survival over 24 months showed good osseointegration. Fifty percent of the implant sites were reported to have no skin reactions throughout the 24-month follow-up period. The remaining had a maximum Holgers score of 1 (minor skin reaction), and a single implant site was reported to have an adverse skin reaction (Holgers 2). None of the skin reactions were persistent or were reported to interfere with sound processor use. Postoperative audiological assessment showed improvement in hearing thresholds when comparing the implanted solution to the softband.Conclusion:Single-stage BAHI surgery, followed by early loading of the percutaneous implant, is safe and feasible in children. Introduction Bone-anchored hearing implants (BAHIs) have revolutionized auditory rehabilitation for patients with conductive or mixed hearing loss. First introduced in 1977, percutaneous BAHIs have undergone significant advances in implant design and surgical technique to improve osseointegration and reduce complications.1–3 In adults, single-stage implantation with early sound processor loading is now routine, with mounting evidence supporting its safety and effectiveness.4,5 In pediatric patients, however, the adoption of early loading protocols has been slower.6 Children are typically considered at higher risk for implant failure due to their thinner, more malleable cranial bone and increased likelihood of trauma. As a result, conventional pediatric protocols have favored 2-stage surgeries and delayed processor loading, often extending the rehabilitation timeline during a critical period for language and social development.6–8 Historically, adults would undergo 2-stage surgery, but it is now commonplace to offer single-stage surgery under local anesthetic, enabling quicker hearing rehabilitation and reduced cost/resource.6 Sound processor loading would occur at least 4 to 6 weeks postoperatively, if not longer. There has been a move toward early loading of the sound processor, which can be done within 3 weeks.5 Single-stage surgery has been undertaken safely in children; however, the time to sound processor loading in some centers can be 3 to 4 months.9,10 Changes to the implant composition have been made with the aim of improving implant stability and allowing early loading protocols.11 So-called wide implants, with a diameter of 4.5 mm, were introduced in 2013 and offered an increased bone-to-implant contact surface compared with previous implants12 and have been shown to be safe and efficacious after early loading at 3 weeks in adults, with no added complications after 1 year.13 In a randomized controlled study comparing the wider 4.5 mm implant with the 3.75 mm implant, the wider implant demonstrated statistically significantly higher implant stability (ISQ) values when compared at 6 months.14 Furthermore, modifications to the implant surface have also contributed to improvements in implant stability. Laser ablation of the implant's surface was shown to improve osseointegration in animal studies,15,16 and laser-ablated implants were introduced in 2015. This study investigates, for the first time, the safety and clinical outcomes of early loading (defined as within 3 to 6 wk postoperatively) of a percutaneous BAHI following single-stage surgery in a nonsyndromic pediatric cohort. The primary objective was to assess implant stability at 6 months compared with at surgery. Secondary outcomes included implant stability at 12 and 24 months, audiological performance, soft tissue tolerance, and patient-reported benefit. Materials and methods Study design and ethical considerations The study was a single-armed, observational, prospective study with a 24-month follow-up period of patients implanted with the investigational device at a single center. Participants attended a screening visit before surgery and follow-up visits at the following time points after surgery: 7 to 10 days, 3 to 4 weeks, 14 to 18 weeks, 6 months, 12 months, and 24 months. The study was approved by the Health and Research Authority, North East – Newcastle and North Tyneside 1 Research Ethics Committee (IRAS ID 239239). All participants and their legal guardians gave informed consent in writing before enrollment. Enrollment occurred from 2018 to 2022, and the final participant completed the 24-month follow-up in 2024. The study has been registered at clinicaltrials.gov (registration ID: NCT03742089). Population Participants were recruited among pediatric patients (5 to 16 y) who had been using a sound processor on a softband for at least 2 weeks and were planned for single-stage BAHI surgery with the investigational implant. Exclusion criteria included patients who could not attend follow-up visits, patients with single-sided deafness (SSD), patients with a disorder or condition that the surgeon felt deemed the patient unfit to participate in the study, as well as patients who received another implant than the investigational implant. Patients could be terminated from the study if they did not want to continue to participate, if they did not complete surgery, if they went on to undergo 2-stage surgery, if they could not attend follow-up visits, if the fixture was lost or if they switched to another brand of sound processor. Investigational device and surgical procedure The implants used in the study were Ponto BHX implants (Oticon Medical AB, Askim, Sweden) with premounted abutments with a length of 9 or 12 mm. Ponto BHX implants without abutments were used as sleeper implants. The BHX implants are wide (4.5 mm) implants with a laser-ablated surface and a length of 3 to 4 mm. The length of the implant is determined based on bone thickness, and the abutment length is dependent on skin thickness, which can be measured before making the incision or in the incision line. The total number of implants used was twice the number of ears/implant sites, as a sleeper implant with a cover screw was implanted in each procedure in accordance with clinical practice where the study was conducted. All operations were performed as a single-stage by the senior surgeon (A.B.) according to the manufacturer’s surgical manual.17 This includes a manual U-shaped incision with a punch hole for the skin-penetrating abutment, followed by a 2-step drilling procedure with a guide drill (3 mm depth) and countersink drill (3 or 4 mm deep, depending on implant length). The implant/abutment complex is placed in the bone using a connector/adaptor on the drill, with a low torque (depending on bone quality), followed by manual tightening with a torque wrench if needed. The sleeper implant (without abutment) is placed 10 to 15 mm from the main implant, using a similar drill technique, and covered with a cover screw. Once the implants are in place, the punch hole in the skin is threaded over the abutment, and the skin is sutured in position. A healing cap is placed over the abutment and removed at 7 to 10 days post-op. Soft tissue reactions Skin assessment was done according to the Holgers scale18 at all follow-up visits. The Holgers scale categorizes soft tissue reactions on a scale of 0 to 4, with a score of 0 indicating no soft tissue reaction and a score of 1 indicating a minor tissue reaction. Scores of 2 to 3 are classified as an adverse reaction, and a score of 4 typically warrants abutment removal. Adverse events were monitored and reported continuously throughout the 24-month follow-up period. Implant stability and survival Implant stability quotient (ISQ) was measured using an Osstell ISQ device (Osstell AB, Gothenburg, Sweden) at surgery, as well as at all follow-up visits, which utilize resonance frequency (RF) to evaluate implant stability; a small rod (SmartPeg, Osstell AB, Gothenburg, Sweden) is inserted into the abutment, and the RF vibrations transmitted through the implant and abutment to the device are translated into an ISQ score on a scale of 1 to 100, where a higher score indicates a more stable implant.19 At each assessment, 2 perpendicular measurements were done, whereof the lower was termed ISQ low (primary outcome) and the higher ISQ high. Patient-reported outcomes At the screening visit, before surgery, while patients were using a sound processor on a softband, the parents/guardians were requested to complete 2 questionnaires: the Parents’ Evaluation of Aural/Oral Performance of Children (PEACH)20 and the Glasgow Children’s Benefit Inventory (GCBI).21,22 The same questionnaires were repeated at 14 to 18 weeks, 6 months and 24 months follow-up. The GCBI scores (total score and 4 subscales) were calculated on a scale of −100 to 100, where scores above 0 indicate a positive impact on quality of life.21,22 The PEACH total score and subscores for quiet and noisy conditions were calculated on a scale of 0% to 100%.20 Audiological assessment and sound processor usage The patients were scheduled for fitting of their sound processor on the abutment 3 to 6 weeks after surgery. Performance audibility was evaluated at the screening visit before surgery, while the patients were using a sound processor on a softband, and at the visit where the sound processor was fitted on the abutment. BC in situ thresholds were extracted from the fitting software (Genie Medical; Oticon Medical AB) at the following frequencies: 250, 500, 750, 1000, 1500, 2000, 3000, 4000, 6000, and 8000 Hz. Free-field thresholds were evaluated in a sound booth at 500, 1000, 2000, 4000, and 6000 Hz, with PTA4 calculated across 500, 1000, 2000, and 4000 Hz. The sound processors had digital feedback cancellation, noise reduction, and automatic directionality turned off during the measurements, and for unilaterally implanted patients, the nonimplanted ear was blocked. Statistical analysis The primary outcome was ISQ low at 6 months, compared with at surgery. On the basis of previous experiences, a 5-point change in ISQ was expected and deemed clinically relevant. A conservative rho of 0.1 was assumed, and with an alpha of 5% and power of 80%, it was determined that at least 14 patients were to be included. Missing data were imputed for the primary outcome (ISQ low) using the last observation carried forward (primary analysis), while a sensitivity analysis was carried out on unimputed data (ITT analysis). For all secondary outcomes, all analyses were done on the available data (ITT without imputation). The distribution of continuous variables has been given as mean±SD, median, minimum and maximum. The conservative Wilcoxon signed-rank test was used to compare changes over time. Data analysis and visualizations were done using Microsoft Excel (Microsoft Excel for Microsoft 365, version 2306) and R (R Foundation for statistical computing, version 4.3.0). Results Study population In total, 15 patients, 6 males and 9 females, aged 7 to 14, were included in the study (Table 1). One patient underwent bilateral BAHI, and therefore the total number of implants was 16. The majority had unilateral acquired conductive and did not have any significant comorbidities besides mild eczema or allergy (Table 1). One patient was lost to follow-up after the 7- to 10-day visit, but available data are included in all analyses, and data from subsequent visits are treated as missing data (Supplemental Table 1, Supplemental Digital Content 1, http://links.lww.com/MAO/C477). Two patients had delayed outcome assessment of the primary endpoint (visit window deviation due to the COVID-19 pandemic), but as a sensitivity analysis did not reveal an impact of the delay on the analysis and conclusions, the data were included in all analyses. The COVID-19 pandemic further hindered some outcome assessments, leading to some degree of missing data. The number of data points has therefore been specified for each outcome throughout the results section. Table 1Patient demographicsPatients (n=15)Sex Male6 (40 %) Female9 (60 %)Age at surgery10±2.410 (7; 14)Weight (kg)47±4.346 (29; 82)Height (cm)147±14.4141 (131; 176)BMI (kg/m2)21±4.019 (16; 28)BMI z-scorea 1.1±0.81.1 (−0.3; 2.7)Smoking Yes0 No15 (100 %)Ethnicity Caucasian15 (100 %)Hearing loss indication Conductive congenital1 (7 %) Acquired conductive/mixed14 (93 %)Hearing loss Bilateral2 (13 %) Unilateral13 (87 %)Scheduled surgery Bilateral1 (7 %) Unilateral14 (93 %) If unilateral, side: Left4 (29 %) Right10 (71 %)Relevant diseases Mild eczema1 (7 %) Allergy to latex and penicillin1 (7 %)Data are mean±SD, median (min; max), n (%). a Calculated using: https://zscore.research.chop.edu/calcbmi.php Patient demographics Data are mean±SD, median (min; max), n (%). Calculated using: https://zscore.research.chop.edu/calcbmi.php Surgical data A 4 mm long implant was used for all implantations, and abutment lengths were either 9 or 12 mm (Table 2). Skin thickness ranged from 2 to 6 mm, measured by a needle (n=15) or in the incision line (n=1), and 9 or 12 mm abutments were used in all cases. Tissue reduction was not performed in any cases, and no abutment changes were reported during the 24-month follow-up. All procedures were performed under general anesthesia. The implant/abutment complex was inserted using a drill torque of 50 N·cm in all cases, with manual tightening in 9/16 cases. Average surgical time was 38 minutes (range: 25 to 46 min) (Table 2). The rate of intraoperative complications/events was low, with 2 instances of drilling into the vein and 2 instances of dura exposure, without further complications. All patients had dissolvable stitches, which did not require removal. Table 2Surgical dataImplant Sites (n=16)Side for surgery Left5 (31 %) Right11 (69 %)Skin thickness (mm)5±1.3; 5 (2-6)Method for skin thickness measurement With needle before incision15 (94 %) In incision line1 (6 %)Length of surgery (min)38±5.7; 40 (25-46)Complications/events during surgery Dura mater exposure2 (13 %) Drilling into vein2 (13 %)Primary implants (n=16)Sleeper implants (n=16)Implant 4 mm BHX16 (100 %)16 (100 %)Abutment length 9 mm9 (56 %)— 12 mm7 (44 %)—Torque used 50 N·cm16 (100 %)16 (100 %)Manual tightening No7 (44 %)15 (94 %) Yes9 (56 %) If yes, no. turns:≥1 turn: 42 turns: 33 turns: 2 Not reported1 (6 %)Seating Fully seated15 (94 %)16 (100 %) Partially seated1 (6 %)a 0Bone quality Soft2 (13 %)2 (13 %) Medium14 (87 %)14 (87 %)Sleeper implant position, relative to the primary implant 3 o’clock—2 (13 %) 5 o’clock4 (25 %) 6 o’clock5 (31 %) 7 o’clock2 (13 %) 8 o’clock2 (13 %) 12 o’clock1 (6 %)Data is mean±SD; median(range) or n (%). a Due to dura mater exposure. Surgical data Data is mean±SD; median(range) or n (%). Due to dura mater exposure. Implant stability No implant losses occurred throughout the 24-month follow-up period. ISQ low increased over time and was significantly higher at 12 months (p=0.035) and 24 months (p=0.019), compared with at surgery (Fig. 1). A similar pattern was observed for ISQ high (Fig. 1), as well as for both ISQ low and high in a sensitivity analysis of unimputed data (Supplemental Table 2, Supplemental Digital Content 1, http://links.lww.com/MAO/C477). ISQ scores (mean±SD) throughout the 24-month follow-up period. Missing data have been imputed using last observation carried forward (a complete data table, including unimputed data, can be found in the supplemental materials, Supplemental Digital Content 1, http://links.lww.com/MAO/C477). *Significantly higher than at surgery (p<0.05). Postoperative complications and adverse events In all the cases, the incision healed as expected and the healing cap was removed at the 7- to 10-day follow-up visit. One patient reportedly had some scabbing around the implant site, which, once cleaned away, revealed a healthy wound. Another patient was given prophylactic oral antibiotics due to sustaining minor trauma to the implant site, although there was no clinical evidence of infection. There were no reports of numbness, hematoma/bleeding, skin necrosis, wound dehiscence, skin overgrowth, or hair-related problems over the 24-month follow-up. Three adverse events with possible relation to the device or procedure were reported; they consisted of 1 ear infection (treated with antibiotic ear drops) and 2 cases of pain and/or discharge from the abutment site (treated with topical fusidic acid ointment). All were classified as mild and were resolved. Soft tissue reactions Skin assessment according to the Holgers score revealed no or minor skin reactions (Holgers score 0 and 1) in 15/16 implant sites throughout the entire follow-up period, hereof, 8 had scores of 0 throughout the entire study period. The remaining implant was reported to have a Holgers score of 2 at a single visit, which was treated with topical treatment (Trimovate cream). Sound processor fitting and usage On average, the fitting occurred 8 weeks after surgery (median 4 wk, range: 3 to 43 wk) and in 10/16 cases (63%), the fitting occurred within the protocol-defined visit window (3 to 6 wk after surgery). In the remaining cases, fitting happened 7, 9, 13, 15, and 43 weeks after surgery. The fitting that occurred 15 weeks postsurgery was delayed due to low ISQ scores. In the remaining delayed cases, no specific reason was recorded, but as the study coincided with the COVID-19 pandemic, it is likely that at least some of the deviations from clinical practice were caused by restrictions related to the pandemic. Audiological performance Audiological assessment was conducted pre- and postsurgery; however, not all patients completed the assessment on both occasions, resulting in a low sample size, and data should be interpreted with caution. As expected, BC in situ thresholds improved postsurgery, indicating more efficient sound transmission through direct bone coupling (Supplemental Table 3, Supplemental Digital Content 1, http://links.lww.com/MAO/C477). At low frequencies (250 to 500 Hz), changes were small and not statistically significant (p>0.05). From 750 Hz upwards, the improvement became more pronounced and statistically significant. The mean threshold improvement ranged from approximately −6 dB at 2000 Hz to −24 dB at 6000 Hz, with the largest gains observed at the higher frequencies (≥3000 Hz) (Supplemental Table 3, Supplemental Digital Content 1, http://links.lww.com/MAO/C477). Free-field thresholds suffered from a higher degree of missing data, but with changes in mean threshold of −4 to 6 dB at frequencies 1000 to 6000 Hz (Table 3). Table 3Aided free-field thresholds measured with the sound processor on a softband (presurgery) and with the sound processor on abutment (at the fitting visit postsurgery)Screening (Softband)Fitting (Abutment)Change From Screening to Fitting500 Hz22±2.720 (20; 25)n=720±7.420 (10; 35)n=110±7.10 (−10; 10) p=1.00n=61000 Hz24±6.920 (15; 35)n=718±6.115 (10; 30)n=11−6±4.9−5 (−15;0) p=0.048n=62000 Hz22±7.025 (15; 30)n=719±6.720 (5; 30)n=11−4±4.9−3 (−10; 0) p=0.174n=64000 Hz26±7.525 (15; 35)n=721±3.220 (15; 25)n=11−6±6.6−5 (−15; 0) p=0.174n=66000 Hz25±5.825 (20; 35)n=722±5.120 (15; 30)n=11−5±3.2−5 (−10; 0) p=0.048n=6PTA4a 24±4.626 (18; 29)n=719±4.218 (15; 29)n=11−4±3.8−3 (−10; 1) p=0.058n=6Data are mean±SD, median (range), and n denotes the number of observations or data pairs. P-values stem from the Wilcoxon signed-rank test. a PTA4 is calculated as the average of 500, 1000, 2000, and 4000 Hz. Aided free-field thresholds measured with the sound processor on a softband (presurgery) and with the sound processor on abutment (at the fitting visit postsurgery) Data are mean±SD, median (range), and n denotes the number of observations or data pairs. P-values stem from the Wilcoxon signed-rank test. PTA4 is calculated as the average of 500, 1000, 2000, and 4000 Hz. Patient-reported outcomes The PEACH subscore for quiet conditions increased over time (screening: 80±11.6, 24 mo: 90±11.2, p=0.033) (Table 4). There was a similar increase in total PEACH score (screening: 76±10.0, 24 mo: 84±7.7, p=0.036), while the increase in the noisy subscore was not significant (screening: 72±11.1, 24 mo: 78±4.3, p=0.106). Table 4Scores from the PEACH (Parents’ Evaluation of Aural/Oral Performance of Children) questionnaireScreening (n=15)14-18 Wk (n=8)6 Mo (n=10)24 Mo (n=8)Screening vs. 14-18 Wk (n=8)a Screening vs. 6 Mo (n=10)a Screening vs. 24 Mo (n=8)a Prerating checklist (yes/no) Has the child been wearing his/her hearing aids? (yes/no)15/08/010/08/0——— Has the child been well/healthy? (yes/no)15/08/010/08/0——— Have the child´s hearing aids been working properly? (yes/no)14/1b 8/09/1b 8/0———PEACH scoresc Quiet score (%)80±11.683 (54; 100)89±11.494 (63; 100)87±12.488 (58; 100)90±11.292 (63; 100) p=0.233 p=0.042 p=0.033 Noisy score (%)72±11.170 (55; 90)78±15.278 (55; 100)81±14.483 (50; 100)78±4.380 (70; 85) p=0.440 p=0.171 p=0.106 Total score (%)76±10.077 (59; 91)84±12.385 (61; 100)84±12.786 (55; 100)84±7.786 (66; 91) p=0.232 p=0.083 p=0.036 a Pairwise comparison of scores using the Wilcoxon signed-rank test, n denotes the number of data pairs available for the test. b Same patient answering “no” on both occasions. At screening, no reason was given; at 6 months, issues with high-pitch noises leading to replacement of sound processor were reported. c Data are mean±SD and median (min-max), scores are calculated % of maximum score (scale 0% to 100%). Scores from the PEACH (Parents’ Evaluation of Aural/Oral Performance of Children) questionnaire Pairwise comparison of scores using the Wilcoxon signed-rank test, n denotes the number of data pairs available for the test. Same patient answering “no” on both occasions. At screening, no reason was given; at 6 months, issues with high-pitch noises leading to replacement of sound processor were reported. Data are mean±SD and median (min-max), scores are calculated % of maximum score (scale 0% to 100%). For GCBI, the mean total score and all subscale scores were above 0 at screening, indicating a positive influence of the hearing system already before surgery (Table 5). There were no systematic changes in scores over time, with the exception of the psychosocial score, which was significantly higher at 6 months compared with before surgery (mean 64 vs. 3, P=0.014). At 24 months, the score decreased and was no longer significantly higher than before surgery. The total score did not change significantly over time, but, interestingly, it was seen that even though some patients scored negatively before surgery, no negative scores were reported after surgery (Table 5). Table 5Scores of the GCBI questionnaireScreening (n=15)14-18 Wk (n=8)6 Mo (n=9)24 Mo (n=8)Screening vs. 14-18 Wk (n=8)a Screening vs. 6 Mo (n=9)a Screening vs. 24 Mo (n=8)a Total score25±22.835 (−17; 56)34±13.032 (13; 52)40±18.635 (15; 67)23±16.218 (6; 60) p=0.245 p=0.127 p=0.483Psychosocial score3±39.910 (−80; 80)43±35.325 (0; 90)64±28.780 (10; 100)11±36.60 (−50; 70) p=0.553 p=0.014 p=0.944Physical health score24±18.920 (−10; 80)29±16.920 (20; 70)30±11.520 (20; 50)36±22.925 (20; 90) p=0.584 p=0.203 p=0.423Behavior score44±33.236 (−7; 93)37±24.936 (0; 71)42±30.036 (0; 93)29±24.225 (−7; 79) p=0.042 p=0.191 p=0.108Vitality score25±25.825 (−33; 67)29±18.621 (17; 75)31±25.733 (−17; 67)20±18.117 (0; 58) p=1.00 p=0.441 p=0.623Data are mean±SD and median (min-max). a Pairwise comparison of scores using the Wilcoxon signed-rank test, n denotes the number of data pairs available for the test. Scores of the GCBI questionnaire Data are mean±SD and median (min-max). Pairwise comparison of scores using the Wilcoxon signed-rank test, n denotes the number of data pairs available for the test. Discussion This prospective single-center study is the first to report on early loading following single-stage BAHI surgery using a laser-ablated percutaneous implant system in a pediatric population. The results show that early loading in children aged 7 to 14 years is both safe and clinically feasible, with no implant losses and low complication rates. Audiological and patient-reported outcomes were positive over the 24-month postoperative period. The results of the present study challenge traditional timelines that often extend to 3 to 6 months. Furthermore, the prospective design and 24-month follow-up provide robust longitudinal data on implant survival, soft-tissue outcomes, and audiological benefit, offering stronger evidence than the predominantly retrospective or short-term studies available to date.23 No implant losses were observed in the 24-month follow-up period, which is notable given the known increased risk of implant failure in children due to thinner bone, greater activity levels, and potential challenges with osseointegration. This finding compares favorably with existing literature, where pediatric implant survival rates range between 86.7% and 95.4% depending on surgical technique, patient comorbidity, and follow-up period.23–26 Implant stability, assessed by ISQ values, was found to be relatively high at surgery and increased slightly over time, reaching statistical significance at 24 months. These results suggest that early loading does not compromise implant stability, consistent with prior reports in adults5,27 and select pediatric populations using wider, surface-modified implants.25 While some data were missing and imputed, the overall ISQ trend supports the hypothesis that the implant provides robust mechanical anchorage suitable for early activation. There were no intraoperative complications leading to long-term morbidity. Two instances of dura exposure and 2 of venous bleeding were managed uneventfully. These results reinforce the safety of a single-stage surgical protocol in appropriately selected pediatric patients and are comparable to other studies of single-stage BAHI surgery in children.10,28 Soft tissue outcomes were favorable, with 50% of implants showing no skin reactions and only one case of a transient Holgers grade 2 reaction. No cases of infection, wound dehiscence, or device-related pain were observed. Furthermore, there were no abutment losses, removals, or exchanges throughout the follow-up period. These findings reflect excellent soft tissue tolerance and compare well with previous reports that cite higher rates of skin-related complications in pediatric BAHI cohorts, although large differences have been observed (0% to 89% across studies) in a systematic review of BAHI efficacy in children.10,24,25 Audiological outcomes were consistent with the literature. Aided free-field thresholds and bone conduction in situ thresholds improved postoperatively compared with softband use, although some differences did not reach statistical significance, likely due to limited sample size. This is comparable to other studies in children looking at improved speech perception with an implant abutment compared with a softband.8,29 Importantly, subjective benefit—as assessed by PEACH and GCBI questionnaires—showed sustained or improved performance and perceived quality of life over 24 months. The significant improvement in psychosocial scores at 6 months on the GCBI underscores the broader developmental and emotional impact of early auditory rehabilitation in children. Parental reports corroborated the clinical findings, with most children/parents perceiving a benefit from surgical intervention compared with softband use. Limitations The primary limitation of this study is the small sample size (15 patients, 16 implants). This study, unlike some within the literature, included only nonsyndromic children and children without intellectual disability, of which higher rates of implant loss have been reported.30 This restricts the generalizability of the findings. Missing data, particularly in ISQ and patient-reported outcome measures, may have influenced the statistical power of some analyses. The study was conducted at a single center with a single experienced surgeon, potentially limiting reproducibility. The follow-up period was 24 months; however, longer-term outcomes regarding implant survival, device performance, and psychosocial benefits would provide a more comprehensive picture of safety, efficacy, and real-world benefit, increasing the overall credibility and generalizability of the study’s conclusions. Conclusion This study supports a paradigm shift in pediatric BAHI practice toward single-stage surgery with early loading, thereby eliminating the need for a second-stage procedure or sleeper fixture. The findings indicate that, with appropriate implant selection, osseointegration is sufficient to support early processor activation without an increased risk of failure or complications. Given the critical role of early auditory stimulation in speech and language development, minimizing the interval between surgery and processor fitting is particularly advantageous in pediatric patients. Avoiding a second surgical procedure reduces the burden on both the child and the health care system, making this approach clinically effective and resource-efficient. Further validation through larger, multicenter studies comparing single-stage early and standard loading with extended follow-up is warranted. These studies should evaluate the long-term safety and efficacy of early loading protocols across broader pediatric populations, including those with syndromic diagnoses or comorbidities. Cost-effectiveness analyses comparing single-stage surgery with early activation to traditional 2-stage protocols are also recommended. Funding The study was sponsored by Oticon Medical AB (Askim, Sweden).